Collegium Pharmaceutical announced its Q3 2025 financial results on November 6, 2025, reporting record quarterly net revenue of $209.4 million, up 31% year‑over‑year. The company’s flagship ADHD product, Jornay PM, generated $41.8 million in net revenue, a 20% increase from the same period last year, while its core pain portfolio delivered $167.6 million, up 11% YoY.
The announcement also revealed that Collegium has raised its full‑year 2025 net revenue guidance to a range of $775–$785 million and its adjusted EBITDA guidance to $460–$470 million. Cash, cash equivalents and marketable securities stood at $285.9 million as of September 30, 2025, underscoring a strong liquidity position.
These results underscore the company’s successful pivot from a pain‑management focus to a diversified biopharmaceutical model, with Jornay PM emerging as a key growth driver. The record revenue growth across both the ADHD and pain segments signals robust demand and effective commercial execution, while the guidance lift reflects management’s confidence in continued double‑digit top‑line expansion.
Collegium will host a conference call and live audio webcast at 8:00 a.m. ET on November 6, 2025, to discuss the results in more detail.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.